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Identity 
Other names: ICF, ICF1, M.HsaIIIB 
HGNC (Hugo): DNMT3B 
Location: 20q11.21 
Note 
DNA (cytosine-5)-methyltransferase 3B (DNMT3B) 
is one of the three known DNA methyltransferases 
with catalytic activity.  
This enzyme is responsible for the de novo 
methylation of DNA, particularly during 
embryogenesis (Okano et al., 1999). In fact, 
DNMT3B adds methyl groups to CpG dinucleotides 
of unmethylated DNA for establishment of new 
methylation pattern in genomic DNA. DNMT3B 
level is profoundly increased in various tumor cell 
lines and in numerous types of human cancers, 
indicating that it plays an important role in 
tumorigenesis (Turek-Plewa and Jagodzinski, 2005). 
DNA/RNA 
Description 
DNMT3B gene is located on the long arm of 
chromosome 20 at position 11.2 and is composed of 
23 exons and 22 introns. This gene encodes for a 
protein of 853 aa. DNMT3B gene is abundantly 
expressed in embryonic stem cells, but its expression 
is decreased upon their differentiation and remains 
low in adult somatic tissues. 
Transcription 
Primary transcript of DNMT3B gene can be spliced 
five different mRNA isoforms that are DNMT3B1, 
DNMT3B2, DNMT3B3, DNMT3B4 and DNMT3B5. 
 
Figure 1. DNMT3B gene is located on the long arm of chromosome 20 at position 11.2 from the base pair 31350190 to base pair 
31397161. It is composed of 23 exons and 22 introns. 
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Figure 2. A: The general structure of DNMT3B protein. The N-terminal domain contains a proliferating cell nuclear antigen-binding 
domain, a nuclear localization signal, a tetrapeptide PWWP, essential for DNMT binding to chromatin, an ATRX cysteine-rich zinc 
finger DNA-binding motif and a polybromo homology domain (PHD) targeting DNMT3B to the replication foci. The C-terminal catalytic 
domain of DNMT3B is characterized by the presence of 6 conserved amino acid motifs, namely I, IV, VI, VIII, IX and X. Motifs I and X 
form S-adenosylomethionine binding site, motif IV binds cytosine at the active site, motif VI possesses glutamyl residue donating 
protons, and motif IX maintains the structure of the target recognition domain (TRD) usually located between motifs VIII and IX, that 
make base-specific contacts in the major groove of DNA (Turek-Plewa and Jagodzinski, 2005). B: The results from alternative 
splicing of exons 10, 21 and/or 22, have reported several different transcripts of DNMT3B. These isoforms are: DNMT3B1, 
DNMT3B2, DNMT3B3, DNMT3B4 and DNMT3B5. DNMT3B1 and DNMT3B2, contain all the highly conserved motifs I, IV, VI, IX and 
X, are enzymatically active in DNA methyltransferase essays. DNMT3B3, which lacks parts of motif IX, appears to be inactive 
enzyme. DNMT3B4 and DNMT3B5, encode truncated proteins that lack motifs IX and X, are presumably inactive as well. The lack 
motifs in DNMT3B3, DNMT3B4 and DNMT3B5 are a consequence of lack 21-22, 21 or 22 exons, respectively (Xie et al., 1999; 




DNMT3B protein is structured with N-terminal 
regulatory and C-terminal catalytic domains that are
linked by repeated GK dipeptides (Glycine-Lysine-
repeats). The N-terminal domain possesses nuclear 
localization signal sequence (NLS) responsible for 
nucleus DNMT3B localization. The N-terminal 
domain plays a regulatory role, and contains a 
proliferating cell nuclear antigen-binding domain. 
This N-domain also contains a cysteine rich zinc 
finger DNA binding motif (ATRX), a polybromo 
homology domain (PHD) targeting DNMT3B to the 
replication foci and a PWWP tetrapeptide  
chromatin-binding domain (Margot et al., 2000). The 
two halves are packed against each other to form a 
single structural module that exhibits a prominent 
positive electrostatic potential. The PWWP domain of 
DNMT3B alone binds DNA in vitro, probably 
through its basic surface, and DNMT3B binds DNA 
stronger than a mutant without the domain. In 
addition, the PWWP domain seems to target the de 
novo methyltransferases to chromatin. The C-
terminal domain contains six conservative motifs I, 
IV, VI, VIII, IX and X. Motif I and X are involved in 
the formation of the S-adenosylomethionine binding 
site. Motif IV binds the substrate cytosine at the 
active site. Motif VI contains the glutamyl residue 
serving as a proton  
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donor. Motif IX maintains the structure of the target 
recognition domain (TRD). Motif VIII's function is 
unclear (Xie et al., 1999). 
The intracellular distribution of DNMT3B enzyme is 
rather dynamic throughout the cell cycle, indeed this
enzyme is diffusely distributed throughout the 
nucleoplasm during most of G1, associates with 
subnuclear sites of DNA replication during S-phase 
(Leonhardt et al.,1992), and binds to chromatin, with 
preference to pericentric heterochromatin, during G2 
and M-phases (Easwaran et al., 2005). 
Description 




DNMT3B is expressed at very low levels in most 
tissues except the testis, thyroid and bone marrow 
(Xie et al., 1999). DNMT3B level is profoundly 
increased in various tumor cell lines, indicating that it 
plays an important role in tumorigenesis (Robertson 
et al., 1999; Hermann et al., 2004). DNA methylation 
is a covalent chemical modification, resulting in the 
addition of a methyl (CH3) group at the carbon 5 
position of the cytosine ring. DNMT3B uses S-
adenosyl-L-methionine (AdoMet) as the source of the 
methyl group being transferred to the DNA bases. 
The methyl group of S-adenosylomethionine is bound 
to a sulphonium atom, which thermodynamically 
destabilizes the molecule and makes the relatively 
inert methylthiol of the methionine moiety very 
reactive towards nucleophilic attack by nitrogen, 
oxygen and sulphur atoms or activated C atoms 
(carbanions). 
DNMT3B may also interact with DNMT1 and 
activate HDAC1, which deacetylates histones and 
represses gene transcription.  
This indicates that DNMT3B may be involved in 
chromatin remodeling associated with the modulation 
of gene transcription. DNMT3B can also effectively 
methylate C to m5C post-replicatively in 
unmethylated DNA. During or after replication, DNA 
regions may bind sequence-specific proteins which 
block the attachment of the methyl group to CpG 
dinucleotide and the formation of methylation 
patterns unique for each tissue.  
The existence of DNMT3B isoforms suggests that 
other factors can be involved in the binding of 
DNMT3B to a particular DNA region. Consequences 
of alternative splicing on DNMT3B's ability to 
interact with DNMT3L. DNMT3L stimulates the 
catalytic activity of DNMT3A and DNMT3B 
methyltransferases (Suetake et al., 2004). DNMT3L 
binds to the carboxyl-terminal part of DNMT3B and 
increases the level of activity of this enzyme (Suetak  
et al., 2004). 
Homology 
DNMT3B exhibit a high degree of primary structure 
homology with DNMT3A. Structurally, DNMT3B 
and DNMT3A have a similar organization, with 
conserved domains: the long N-terminal region 
contains a PWWP domain and a cysteine-rich PHD 
zinc finger domain and the C-terminal catalytic 
domain. The same NLS and ATRX sequences were 




ICF syndrome (standing for Immunodeficiency, 
Centromere instability and Facial anomalies 
syndrome) is a rare autosomal recessive immune 
disorder caused by mutations of the gene DNMT3B. 
Therefore, the DNMT3B mutations, like A766P and 
R840Q, observed in patients are the likely underlying 
cause of their ICF phenotypes (Xie et al., 2006). 
This hereditary syndrome is characterized by 
centromeric instability of chromosomes 1, 9, and 16 
is associated with abnormal hypomethylation of CpG 
sites in their pericentromeric satellite regions (Hansen 
et al., 1999). At the molecular level, in patient DNA, 
sequences such as the pericentromeric classic satellite 
repeats of pericentromeric regions are 
hypomethylated, which attributes to reduced 
enzymatic activity of the mutant proteins (Jeanpierre 
et al., 1993; Gowher and Jeltsch, 2002). 
Several polymorphisms were detected at the promoter 
region of DNMT3B gene and may influence its 
activity in DNA methylation and increase the 
susceptibility to several cancers. DNMT3B promoter 
polymorphisms influence on promoter 
hypermethylation of genes in other interacting 
pathways, such as cell cycle, apoptosis, or other DNA 
repair pathways and may increase level of DNA 
damage which contributes to an increased risk for 
cancers. For example, C>T (rs406193), -283T>C 
(rs121909506), -579G>T (rs2424909), -579G>T 
(rs2235758) and G39179T DNMT3B polymorphisms 
influence DNMT3B expression, thus contributing to 
the genetic susceptibility to different cancers (Lee et 
al., 2005; Fan et al., 2008; Montgomery et al., 2004; 
de Vogel et al., 2009; Daraei et al., 2011). 
The common DNMT3B -149C>T (rs2424913) 
polymorphism was found to significantly increase 
DNTM3B promoter activity. This up-regulates the 
expression of the gene and may in turn lead to 
aberrant methylation of CpG islands in some tumor 
suppressor genes (Montgomery et al., 2004). It was 
associated with an increased risk for lung cancer 
(Shen et al., 2002), prostate cancer (Singal et al., 
2005), and colorectal polyps, including colorectal 
adenomas (Jung et al., 2008), or with prognosis of 
head and neck cancer (Wang et al., 2004). 
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DNMT3B may play an oncogenic role during 
tumorigenesis, and its genetic variants have been 
consistently associated with risk of several cancers. 
Overexpression of DNMT3B may result in promoter 
hypermethylation of multiple tumor suppressor genes 
and ultimately lead to lung tumorigenesis and poor 
prognosis especially among smoking patients (Lin et 
al., 2007; Palakurthy et al., 2009). 
Polymorphisms and haplotypes of the DNMT3B gene 
may influence DNMT3B activity on DNA 
methylation, thereby modulating the susceptibility to 
lung cancer. The -283T>C and -579G>T 
polymorphisms in the DNMT3B promoter, and their 
haplotypes were significantly associated with the risk
of adenocarcinoma of the lung (Lee et al., 2005). 
These mutations up-regulate DNMT3B expression, 
resulting in a predisposition towards aberrant de novo 
methylation of CpG islands in tumor suppressor 
genes and DNA repair genes (Lee et al., 2005; Shen 
et al., 2002). 
Breast cancer 
Note 
DNMT3B expression levels are significantly higher  
in breast cancers than in normal breast tissues, 
suggesting a role of this enzyme in breast 
tumorigenesis (Fig. 3) (Girault et al., 2003; Butcher 
and Rodenhiser, 2007; Ben Gacem et al., 2012). 
DNMT3B overexpression is correlated to the 
epigenetic inactivation of several tumor suppressor 
genes and to the aggressive phenotype in breast 
tumors (Roll et al., 2008; Ben Gacem et al., 2012). 
Some polymorphisms are associated to the 
development of breast tumors. DNMT3B C46359T 
polymorphism has been correlated to women with 
early-onset breast cancer, bilateral breast cancer and 
with a family history of the disease (Montgomery et 
al., 2004; Wang et al., 2004). 
Leukemia and lymphomas 
Note 
DNMT3B is substantially overexpressed in leukemia 
cells than in normal bone marrow cells (Mizuno et 
al., 2001). DNMT3B overexpression was correlated 
to hypermethylation of several tumor related genes i   
diffuse large B-cell lymphomas and in B-cell chronic 
lymphocytic leukemia (Amara et al., 2010; Kn et al.,
2004). In B-cell chronic lymphocytic leukemia, 
DNMT3B overexpression was identified as an 
independent prognostic factor for predicting 
shortened survival of patients (Amara et al., 2010). 
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Hepatocellular carcinoma 
Note 
DNA hypomethylation on pericentromeric satellite 
regions is one of the earliest events during 
hepatocarcinogenesis. Overexpression of DNMT3B4 
isoform and elevation of the ratio of DNMT3B4 
mRNA to DNMT3B3 mRNA were both significantly 
correlated with the degree of DNA hypomethylation 
on pericentromeric satellite regions in hepatocellular 
carcinoma (Saito et al., 2002). DNMT3B4 
overexpression induces DNA demethylation on 
pericentromeric satellite regions even in precancerous 
stages and may play critical roles in the development 
of hepatocellular carcinoma through chromosomal 
instability and aberrant expression of cancer-related 
genes (Saito et al., 2002). 
Colorectal cancer 
Note 
The levels of DNMTs mRNA/protein in colorectal 
carcinomas are significantly higher than in 
noncancerous colorectal tissues and the highest 
expression range was observed with DNMT3B (Eads 
et al., 1999; Linhart et al., 2007; Nosho et al., 2009; 
Huidobro et al., 2012). The CpG island methylator 
phenotype (CIMP) in colorectal cancer is 
characterized by a widespread CpG island 
methylation. DNMT3B contributes to CpG island 
methylation, which may eventually lead to the 
development of CIMP-high colorectal cancer (Nosho 
et al., 2009; Schmidt et al., 2007). 
In hereditary nonpolyposis colorectal cancer, the 
DNMT3B gene contains a C-to-T single nucleotide 
polymorphism -149 bp from the transcriptional start 
site that may result in increased promoter activity of 
the gene (Shen et al., 2002). The DNA mismatch 
repair mutation carriers who also carried at least one
T allele for the DNMT3B promoter region C-to-T 
polymorphism had a 2-fold higher risk for colorectal 
cancer by year than those who were homozygous for 
the wild-type DNMT3B allele (Jones et al., 2006). 
Facial anomalies syndrome (ICF) 
Note 
Facial anomalies syndrome (ICF) is an autosomal 
recessive disease. DNMT3B gene is often the site of 
ICF mutations (Ehrlich et al., 2006). ICF syndrome 
presents with variable combined immunodeficiency, 
mild facial anomalies and extravagant cytogenetic 
abnormalities with largely affect the pericentric 
regions of chromosomes 1, 9 and 16. These 
pericentric regions contain a type of satellite DNA 
termed classical satellite, or satellites 2 and 3. It is 
normally heavily methylated, but is nearly completely 
unmethylated in DNA of ICF patients. In addition to 
classical satellite, demethylation of DNA in ICF 
patients is also seen at CpG islands on the inactivate 
X chromosome in females (Ehrlich et al., 2008). 
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